![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
Recently, domestic and international 3D printing has made breakthroughs in biomedical research, and biological 3D printing technology has become more mature. The launch of 3D printed tablets in the United States has made this technology even more subversive of people's worldview. We believe that 3D printing technology will change people's lives better and faster.
As bio-based 3D printing continues to heat up, many startups have invested in this area with their own innovative projects. Recently, another company, Aspect Biosystems, from Vancouver, Canada, received a seed investment to further develop their body tissue printing technology.
It is understood that Aspect Biosystems was founded in 2013, and their ultimate goal is to print complete human organs in 3D. Currently, the company is developing 3D printed human tissue. These organizations will be used by pharmaceutical companies for drug testing. The company's current goal is to improve the predictive accuracy of clinical drug discovery methods, and the long-term goals include eliminating animal experiments on drugs and creating human organs for medical assistance.
There is no doubt that Aspect's project is very original, but it also means that financial support is essential. Fortunately, the company just got its first round of seed funding this week. They plan to use the funds for the development of next-generation bio 3D printing technology and the commercialization of their services and products.
"Aspect's breakthrough in 3D bioprinting has impressed us, and we believe they have the ability to create highly advanced structural organizations in the short term," said Todd Farrell, chairman of UBC Seed Funds.
Although the amount of funds has not yet been made public, Aspect CEO Konrad Walus believes that this has been a big step forward.
Walus also revealed some other developments, including their recent collaboration with a leading pharmaceutical company and an agreement with the company on the 3DAirway ALI(TM) Human Respiratory Tissue.
“Aspect's goal is to impact multiple markets, including clinical drug development, personalization, cosmetics and regenerative medicine,†Walus said. “We have seen the key to future developments, and it will truly demonstrate bio 3D printing. The potential value of the business sector."
In the following year, Aspect expects to expand their customer base and work with other companies in the industry. They will also disclose some of the latest data on additional models currently in development.
“Biological 3D printing is benefiting from the rapid development of cell biology and tissue engineering of many important tissue components,†says Walus. “So we expect rapid development of new functions in 3D printed biological tissue and increase its physiological relevance. Aspect's unique printer-based laboratory technology allows us to understand structures that are otherwise impossible."
Interactive Flat Panel,interactive touch screen,interactive screen,interactive panel,interactive touch monitor
Guangzhou Ruixin Touch Control Technology Co., Ltd. , https://www.weetaach.com